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Abstract
Background: Natural health products (NHP) use may have implications with respect to adverse effects, drug interactions
and adherence yet the prevalence of NHP use by patients with acute cardiovascular disease and the best method to
ascertain this information is unknown.
Objective: To identify the best method to ascertain information on NHP, and the prevalence of use in a population with
acute cardiovascular disease.
Methods: Structured interviews were conducted with a convenience sample of consecutive patients admitted with acute
cardiovascular disease to the University of Alberta Hospital during January 2009. NHP use was explored using structured
and open-ended questions based on Health Canada’s definition of NHP. The medical record was reviewed, and
documentation of NHP use by physicians, nurses, and pharmacists, compared against the gold-standard structured
interview.
Results: 88 patients were interviewed (mean age 62 years, standard deviation [SD 14]; 80% male; 41% admitted for acute
coronary syndromes). Common co-morbidities included hypertension (59%), diabetes (26%) and renal impairment (19%).
NHP use was common (78% of patients) and 75% of NHP users reported daily use. The category of NHP most commonly
used was vitamins and minerals (73%) followed by herbal products (20%), traditional medicines including Chinese
medicines (9%), homeopathic preparations (1%) and other products including amino acids, essential fatty acids and
probiotics (35%). In a multivariable model, only older age was associated with increased NHP use (OR 1.5 per age decile
[95%CI 1.03 to 2.2]). When compared to the interview, the highest rate of NHP documentation was the pharmacist history
(41%). NHP were documented in 22% of patients by the physician and 19% by the nurse.
Conclusions: NHP use is common in patients admitted with acute cardiovascular disease. However, health professionals do
not commonly identify NHP as part of the medication profile despite its potential importance. Structured interview appears
to be the best method to accurately identify patient use of NHP.
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Introduction
Complementary and alternative medicine (CAM) use has risen
due to local, national and international availability of CAM
practitioners, manufacturers and CAM products themselves [1].
Natural health products (NHP) are an important aspect of the
CAM practitioner’s practice and recently Health Canada’s
Natural Health Products Directorate (NHPD) defined NHP as
vitamins and minerals, herbal remedies, homeopathic medicines,
traditional medicines such as traditional Chinese medicines and
other products including probiotics, amino acids and essential fatty
acids [2]. Although variable definitions exist, CAM has been
defined by the United States’ National Institutes of Health
National Center for Complementary and Alternative Medicine
as ‘‘a group of diverse medical and health care systems, practices,
and products that are not generally considered part of conven-
tional medicine.’’ (http://nccam.nih.gov/health/whatiscam, ac-
cessed April 11, 2011) Whereas mainstream medications have
often undergone rigorous evaluation and surveillance, NHP has
traditionally relied upon patient or practitioner preferences,
anecdotal evidence, often with limited data on clinical effectiveness
or safety.
In the general population, CAM use had been the main focus of
prior research, whereas NHP use has not previously been well
defined and have been mixed with other supplemental and over-
the-counter medicines. While CAM research has shed light on the
emergence and increasing use of dietary supplements, herbal and
homeopathic products [3,4], and the incidence or prevalence
of use by patients with cardiovascular disease is common [5–11],
few high quality studies exploring NHP use have been done.
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methods may not capture detail necessary to draw conclusions on
the nature of use, type of NHP used or accuracy of information
obtained (for example, if patients do not consider vitamins to be
NHP). The life-threatening nature of cardiovascular disease with
its impact on life-style, the abundance of its pharmacologic therapy
with increasing chance of drug-drug interactions and the
coexistence of diverse co-morbidities make cardiovascular patients
a special population where NHP use should be known.
Accordingly, we conducted a study describing the prevalence of
NHP use in patients with acute cardiovascular disease in a large
tertiary care hospital using direct structured interview. We also
sought to determine the possible predictors of NHP use and the
most reliable method of NHP in-hospital documentation by
comparing the direct interview to other healthcare professional
documentation.
Methods
Study Population
All patients with acute cardiovascular disease admitted to the
University of Alberta Hospital between 7
th January to 6
th February
2009 were initially approached for participation in this study. To
be eligible for the study, patients had to be older than 18,
hospitalized for an acute cardiovascular condition, able to provide
informed consent, read and speak English, and responsible for self-
administration of medications. There were no other inclusion or
exclusion criteria. If a patient was admitted more than once during
the study period, the first admission was considered the index visit.
Procedures and Data
The study protocol consisted of structured interviews inquiring
about NHP use and pattern of use, followed by chart review for
further data collection. All interviews were conducted by one
interviewer (AA) to provide internal consistency on NHP generic
names and categorization. The interviews were all carried out at
the patient bedside setting. The interviewer received training,
instructions and guidelines on NHP prior to the study by local
NHP experts including a pharmacist with experience in NHP.
This pharmacist accompanied the interviewer on random
interviews (6% of interviews) for quality assurance.
The interview consisted of structured and open-ended questions
about any NHP use, frequency of use, and patients were asked to
provide the names of all NHP they used. This method has been
previously used [5]. To facilitate the patient’s understanding of the
NHP, all patients were shown a pamphlet demonstrating pictures
of the different NHP categories based on NHP definition by
Health Canada’s Natural Health Products Directorate (NHPD) in
2004 [2]. The frequency of use was divided into daily, weekly,
monthly or seasonal and the patients were only considered an
NHP user if they had used an NHP in the last year. If the patient
provided a trade name, the interviewer used multiple websites to
identify the product constituents.
After discharge, the medical record for each patient was
examined to extract demographic and clinical data, and to chart
NHP as documented in the pharmacist history, the admitting
physician history, and the nurse’s medication list. Each of these
professions does a detailed intake medication history on admission
for all patients.
Statistical Analysis
The prevalence of NHP use in the study population is described
using simple rates. The frequency of NHP intake among users, and
the prevalence of each NHP category and product were further
described. To assess the frequency of in-hospital NHP documen-
tation by clinical staff, the frequency of NHP documentation by
each profession (physician, pharmacist, nurse) was compared
against the structured interview (considered the gold standard)
using Kappa to quantify agreement. Previously defined classifica-
tion of Kappa agreements were none (0), slight (0 to 0.2), fair (0.2
to 0.4), moderate (0.4 to 0.6) and substantial (0.6 to 0.8) [12].
McNemar’s test was used to compare between the proportions of
NHP documentation of the different professions using general
NHP use as a dichotomous variable rather than unique products.
A parsimonious multivariable model was constructed using
univariate predictors from Table 1 (including baseline demo-
graphics, education, median income, medical history, medical
therapy, and discharge diagnosis), which were entered into a
logistic regression model if they had a p-value,0.20. The model
was constructed using stepwise procedure, and results are
presented using odds ratio (OR) and 95% confidence intervals
(95%CI). Data was coordinated, quality assured, and analyzed by
the Epidemiology Coordinating and Research (EPICORE) Centre
at the University of Alberta. The health research ethics board at
the University of Alberta approved the study.
Results
Of 107 patients identified, 11 were not in the target population
(hospitalized for a non-cardiovascular condition, or unable to
provide consent) and 8 refused to participate giving an overall
response rate of 90%; the remaining 88 patients were enrolled and
interviewed. Table 1 shows the demographic and clinical data of
our patients. The mean age was 62 years (standard deviation [SD
14]) and 80% were male. The most common cause of admission
was acute coronary syndrome (41%), and main co-morbidities
included hypertension (59%), diabetes (26%) and renal impair-
ment (19%).
Prevalence and pattern of NHP use
The majority of patients used NHP (n=69, 78%) and Table 2
reports the frequency of NHP use including the frequency of each
NHP category and product used. Vitamins and minerals were the
most commonly used NHP category (n=64, 73%); other NHP
categories frequently used included herbal products (n=18, 20%),
traditional Chinese medicines (n=8, 9%), and others (probiotics,
amino acids and essential fatty acids) (n=31, 35%). With respect
to single NHP use, multivitamins were the predominant NHP used
(n=41, 47%), followed by vitamin D (n=34, 39%) and calcium
supplements (n=31, 35%). Other commonly used NHP included
omega 3 fatty acids (n=16, 18%), probiotics and garlic (n=6, 7%
each). Table 3 depicts the frequency of intake of NHP among
those who used NHP; 75% reported daily intake while the rest had
taken NHP less frequently. In the exploratory multivariable model
to identify patient-level predictors of NHP use, only older age was
associated with increased NHP use (OR 1.5 per age decile [95%CI
1.03 to 2.2]).
Frequency of in-hospital NHP documentation by clinical
staff
When compared to the interview as the gold standard, the
clinical history obtained by the admitting physician, pharmacist or
nurse was generally poor (Table 4). The pharmacist history
recorded NHP use in 41% (n=28) of patients who reported NHP
in the interview (Kappa 0.22, fair agreement), while physicians
and nurses recorded NHP use in 22% (n=15) (Kappa 0.1, slight
agreement) and 19% (n=13) (Kappa 0.08, slight agreement) of
patients, respectively. There was a significant difference between
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the nurse history (p=0.002). Out of 275 unique NHP detected in
the direct interviews, the pharmacist history identified 73 NHP
(27%), the physician history documented 30 NHP (11%) and the
nurse history recorded 33 NHP (12%).
In order to explore reasons for non-documentation, charts were
re-examined and a pharmacist history was identified in only
(n=45, 51%) of patients while the nursing and physician histories
were available in all patients. When this was taken into account
and only patients with a pharmacist history were examined and
compared to direct interview, the pharmacist history recorded
NHP use in (n=28, 70%) of patients who reported NHP in the
interview giving a kappa of 0.34 (fair agreement).
Discussion
Our study demonstrates that NHP use is surprisingly common
in patients with acute cardiovascular disease and that despite
highly prevalent use, health professionals failed to recognize or
record NHP as an important part of the medication profile.
Pharmacists, who are expected to be closest to a gold standard
since their training explicitly incorporates NHP, identified NHP in
only 41% of all NHP users. The potential clinical impacts of
missing this information are unknown, but would include drug
interactions, adverse effects or other side-effects otherwise
attributed to proven efficacious medications. Finally, as the use
of direct structured interviewing was critical to identify use of
NHP: future NHP and CAM studies should incorporate this
methodology.
Table 1. Baseline characteristics and discharge diagnosis.
N( % )
Mean age, years (SD) 62 (14)
Male 70 (79.5)
Marital status single 10 (11)
married or common law 70 (80)
separated, divorced or widowed 8 (9)
Highest Education Less than high school 25 (28)
High school 27 (31)
College/technical school 23 (26)
Undergraduate degree 2 (2)
Postgraduate degree 11 (13)
Annual household income
(Canadian dollars)
,20 000 3 (3)
20 000–40 000 18 (21)
40 000–60 000 12 (14)
.60 000 19 (22)
Not documented 36 (41)
Ethnicity Caucasian 71 (81)
Black 2 (2)
Aboriginal 4 (5)
Hispanic 2 (2)
Asian 4 (5)
Other 5 (7)
Discharge Diagnosis Acute coronary syndromes 36 (41)
STEMI 7 (8)
NSTEMI 22 (25)
Unstable angina 7 (8)
Heart failure 18 (20)
Ventricular arrhythmia 2 (2)
Atrial arrhythmia 4 (5)
Other cardiovascular disease 28 (32)
Comorbidities Diabetes 23 (26)
Hypertension 52 (59)
Hyperlipidemia 44 (50)
Smoking 25 (28)
COPD/Asthma 9 (10)
Musculoskeletal disorder 16 (18)
GERD/PUD 10 (11)
Renal impairment 17 (19)
Hepatic impairment 1 (1)
Values are N (%) unless otherwise stated. STEMI=ST elevation myocardial
infarction. NSTEMI=non-ST elevation myocardial infarction. COPD=chronic
obstructive pulmonary disease. GERD=gastroesophageal reflux disease.
PUD=peptic ulcer disease.
doi:10.1371/journal.pone.0019623.t001
Table 2. Frequency of natural health product use.
N( % )
Total NHP use 69 (78)
NHP use by category vitamins and minerals 64 (73)
herbal products 18 (20)
homeopathy 1 (1)
traditional medicines including
Chinese medicine
8( 9 )
other (probiotics, amino acids, and
essential fatty acids)
31 (35)
NHP use by specific
product
Multivitamins 41 (47)
Vitamin D 34 (39)
Calcium 31 (35)
Vitamin C 24 (27)
Omega 3 16 (18)
Vitamin B complex 11 (13)
Magnesium 9 (10)
Vitamin E 9 (10)
Vitamin B12 6 (7)
Probiotics 6 (7)
Garlic 6 (7)
Zinc 5 (6)
Protein supplements 5 (6)
Glucosamine 5 (6)
Other infrequently used products used included [4 uses each] coenzyme Q10,
and flax oil; hawthorn, chondroitin, ginko biloba, ginseng, and vitamin B6; [2
uses each] serrapeptase enzyme, methylsulfonylmethane, cayenne pepper,
peppermint, green tea, herbal tea, thai tea, folic acid, and replavite; [1 use each]
lutein, white willow bark, motherwort, bilberry, lavender, eucalyptus,
wintergreen, menthol, camphor, opti-i-see eye drops, bromelain, turmeric,
Echinacea, graviola, rat root plant leaf, banana leaf extract, cranberry
supplement, celery herbal, rosemary herbal, seaweed herbal, chamomile tea,
carboxymethylcellulose, collagen supplements, vitamin B50 complex, gelatin,
and agar.
doi:10.1371/journal.pone.0019623.t002
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therefore we focused this study on NHP as it is more likely to
cause side effects and drug-drug interactions with often limited
supportive research-based evidence upon which to rely. In the
general population, national telephone surveys of a representative
population in the United states in 1990 (n=2055 subjects) and
1997 (n=1539 subjects) showed that the prevalence of herbal
medicines increased from 2.5% to 12.1% and megavitamins from
2.4% to 5.5% [13]. A similar Canadian study of 12000 households
found that 26% of a surveyed population had used herbal and/or
homeopathic remedies in 1999, 41% in 2000 and 44% in 2002
[3]. This pattern and prevalence of use led Health Canada to
clearly define NHP as a separate entity in 2004 [2], and using this
NHP definition, a telephone survey in 2005 found that 71% of
Canadians used NHP [14].
Studies of NHP and CAM have discordant results across
populations with cardiovascular disease, geography and method-
ology utilized. In the United States, a subset of patients with
cardiovascular disease derived from the 2002 National Health
Interview survey showed the prevalence of herbal therapies and
multivitamins to be 18% and 3%, respectively [13]. However, a
direct mail out questionnaire to an outpatient cardiovascular
population showed the prevalence of multivitamin to be 68%,
vitamin E 6%, and vitamin C 13% [15]. A study that compared
the use of nonprescription medications by patients with chronic
heart failure showed 59% used vitamins and minerals and 38%
used herbal and health food products [16]. However, in a
developing country, the use of dietary supplements or herbs by
Nigerian patients with hypertension was 96.6% [11]. Given this
variability, standardized methodology should be developed and
adopted for the purpose and population under study.
In previous NHP and CAM studies, the most consistent variable
to correlate with a higher use was female gender [6,13,15,17].
Other less consistent variables from the literature include younger
age groups, higher level of education, and higher income [6]. In
our study, older age was the only variable associated with higher
NHP use in our study of patients with cardiovascular disease, who
were generally older than those surveyed in the general
population. However, given the increasing number of cardiovas-
cular risk factors in younger patients, this may change in the
future. Regardless, all patients should be approached regarding
their use of NHP.
This study demonstrated poor documentation of NHP use by
health professions despite prevalent use by patients and impor-
tance of these products. In order to assess possible drug-drug
interactions, side-effect profiles, patient preferences, affordability
and effect on disease outcomes, the use of NHP has to be identified
as a first step. Failure to identify NHP as part of the medication
profile may lead to continuation in administering costly and widely
available NHP drugs without an evidence base to support their use
in diseases with serious morbidity and mortality. Furthermore,
some of the NHP identified included vitamin C and vitamin E,
both tested in multiple adequately powered randomized trials
and shown to have either no beneficial effect or potential harm
[18–21]. Other NHP could result in serious adverse events such as
bleeding from concurrent use of anti-platelets or anticoagulants
with Ginko-biloba or garlic [22]. Similarly, proven efficacious
medications may also be reduced by a NHP, for example, ginseng
reduces the international normalized ratio (INR) when tested in a
double-blind, placebo-controlled trial of patients taking coumadin
[23]. Unlike pharmaceutical products approved for treatment of a
specific disease and subject to careful scientific, public and
governmental scrutiny, most of the NHP identified have little
published high-quality evidence to support their widespread use.
However, some NHP we identified have undergone extensive
testing and are supported by international guidelines for disease
such as osteoporosis (calcium and vitamin D) whereas others have
been tested in a cardiovascular population and found to be either
neutral (vitamin B complex) or potentially harmful (vitamin C and
vitamin E). Even more concerning is the out-of-pocket expense to
patients (equaling or exceeding that of many medications with a
high grade recommendations from international guidelines).
Finally, vulnerable patients are often susceptible to direct-to-
consumer marketing that allows carefully worded claims of ‘cures’.
What is the reason for the identified gap in documentation?
Previous literature had shown that many patients do not take
initiative to inform health professionals about using NHP or CAM.
Although one study reported that 80% of CAM users claimed that
they had discussed CAM with their physicians,
7 three other studies
showed that over half of patients stated that their physician was
unaware of their CAM use [24,25]. When asked if it is important
to consult a physician about NHP use, only 42% of patients
completely agree and 29% somewhat agree on informing their
physician [14]. Equally important and not previously rigorously
studied, is whether or not health professionals in clinical practice
are aware of the importance of including questions regarding NHP
use in the history obtained at admission to hospital. Our study
suggests that this is poorly documented and may be multifactorial.
The pharmacist history was chosen for further analysis because
it was felt to be the closest clinical resource to the gold standard
interview in identifying NHP use and because of the availability of
pharmacists on the clinical team at our hospital. However, even
this was less than optimal, in part because not all patients received
a pharmacist medication history, but even when available, NHP
were infrequently documented. This suggests that all three
professions that would traditionally record medications on
admission should improve NHP documentation, and education
in both undergraduate and continuing education should empha-
size the importance of this effort.
Table 3. Frequency of NHP intake.
N( % )
Daily 52 (75)
Weekly 7 (10)
Monthly 2 (3)
Seasonal 7 (10)
No response 1 (2)
doi:10.1371/journal.pone.0019623.t003
Table 4. Frequency of natural health products
documentation by clinical staff when compared to direct
structured interview.
Profession N* (%) Kappa (degree of agreement) N** (%)
Pharmacist 28 (41) 0.22 (fair) 73 (27)
Physician 15 (22) 0.1 (slight) 30 (11)
Nurse 13 (19) 0.08 (slight) 33 (12)
*N represents the number of matched histories of natural health product use
(between profession and direct interview).
**N represents the number matched unique NHP products.
doi:10.1371/journal.pone.0019623.t004
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The major strength of this study was the direct structured
interview resulting in a smaller sample size. Direct interview for
research purposes has implications for cost given the time
involved, however, formal comparison of the cost-effectiveness of
this technique versus telephone interview has not been done.
However, comparing this method as a gold standard to the usual
methods of medications documentation was a crucial objective of
this study and thus has broader clinical research implications.
Additional use in the clinical environment will enhance the utility
of this method, as will enhancements in data portability between
clinics, pharmacies, hospitals and patients. This study focused on
duration, type and prevalence of NHP use, however, future studies
should investigate the indication for each NHP use or to
differentiate between prescribed or non-prescribed NHP and
indications for each. We chose to categorize various NHP into
groups, however, due to the nature of NHP categories and
codification, inconsistency of labeling, and nomenclature made
this challenging. NHP manufacturers should be encouraged to
provide monographs similar to that of prescription-based phar-
maceutical medications to aid clarification of the contents, dose,
safety profile and indications as shown by published literature.
This study explored the necessity of future larger studies using
structured interviewing to investigate NHP use and to explore
reasons of poor NHP recognition by medical profession in broader
clinical practice.
Conclusion
NHP use is common in patients admitted with acute
cardiovascular disease. However, health professionals do not
commonly identify NHP as part of the medication profile despite
its potential importance. Structured interview appears to be the
best method to accurately identify patients using NHP.
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